State Street SPDR S&P Pharmaceuticals ETF
XPH
73 hedge funds and large institutions have $101M invested in State Street SPDR S&P Pharmaceuticals ETF in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 10 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
10.75% more ownership
Funds ownership: 52.8% → 63.55% (+11%)
3% more funds holding
Funds holding: 71 → 73 (+2)
3% more capital invested
Capital invested by funds: $98.4M → $101M (+$2.72M)
52% less call options, than puts
Call options by funds: $813K | Put options by funds: $1.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$22.9M |
| 2 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
+$12M |
| 3 |
FCBT
First Citizens Bank & Trust
Raleigh,
North Carolina
|
+$2.53M |
| 4 |
Envestnet Portfolio Solutions
Chicago,
Illinois
|
+$2.26M |
| 5 |
JP Morgan Chase
New York
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$35.5M |
| 2 |
Citigroup
New York
|
-$2.27M |
| 3 |
RW
Rockport Wealth
Fairview Park,
Ohio
|
-$1.22M |
| 4 |
GS
GTS Securities
New York
|
-$1.12M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.02M |
XPH Hedge Fund Activity: Q4 2024 in Review
73 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2024, worth a combined $101M — up 2.8% from $98.4M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new XPH positions and 10 closed out — a net gain of 3 holders — while 26 added to existing stakes and 14 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $22.9M. The largest seller was Clal Insurance, exiting entirely with an estimated $35.5M sold.
- 73 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2024, up from 71 in Q3 2024.
- Funds reported $101M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2024, up 2.8% quarter-over-quarter.
- 13 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2024 and 10 closed out, a net change of +3 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2024 was Morgan Stanley, an estimated $22.9M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2024 was Clal Insurance, an estimated $35.5M sold.
Based on aggregated 13F filings for Q4 2024.